{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T09:30:18Z","timestamp":1792661418012,"version":"4.5.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,1,7]],"date-time":"2016-01-07T00:00:00Z","timestamp":1452124800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs - Real World Outcomes"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1007\/s40801-015-0056-z","type":"journal-article","created":{"date-parts":[[2016,1,7]],"date-time":"2016-01-07T12:25:08Z","timestamp":1452169508000},"page":"1-6","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Traditional Anticoagulants and Hair Loss: A Role for Direct Oral Anticoagulants? A Review of the Literature"],"prefix":"10.1007","volume":"3","author":[{"given":"Magdalena M.","family":"Watras","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jignesh P.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roopen","family":"Arya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,1,7]]},"reference":[{"key":"56_CR1","volume-title":"Prescribing guidelines in psychiatry","author":"DM Taylor","year":"2015","unstructured":"Taylor DM, Paton C, Kapur S. Prescribing guidelines in psychiatry. 12th ed. London: Wiley Blackwell; 2015.","edition":"12"},{"issue":"5078","key":"56_CR2","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1136\/bmj.1.5078.1034","volume":"1","author":"GR Tudhope","year":"1958","unstructured":"Tudhope GR, Cohen H, Meikle RW. Alopecia following treatment with dextran sulphate and other anticoagulant drugs. Br Med J. 1958;1(5078):1034\u20137.","journal-title":"Br Med J."},{"issue":"22","key":"56_CR3","first-page":"509","volume":"83","author":"R Fischer","year":"1953","unstructured":"Fischer R, Bircher J, Reich T. Falling of hair after anticoagulant therapy. Schweiz Med Wochenschr. 1953;83(22):509\u201311.","journal-title":"Schweiz Med Wochenschr."},{"key":"56_CR4","unstructured":"VigiBase [Online]. Available from: http:\/\/www.vigiaccess.org\/\/ . Accessed 31 Aug 2015."},{"key":"56_CR5","unstructured":"Summary of Product Characteristics: Warfarin, Amdipharm Mercury Company Limited April 2014. http:\/\/www.medicines.org.uk . Accessed 31 Aug 2015."},{"key":"56_CR6","unstructured":"Summary of Product Characteristics: Heparin, Baxter Healthcare Limited. April 2015 . http:\/\/www.medicines.org.uk . Accessed 31 Aug 2015."},{"issue":"5","key":"56_CR7","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/europace\/eut083","volume":"15","author":"H Heidbuchel","year":"2013","unstructured":"Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, et al. European Heart Rhythm Association practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2013;15(5):625\u201351.","journal-title":"Europace."},{"key":"56_CR8","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1001\/archderm.1961.01580080005001","volume":"83","author":"AM Kligman","year":"1961","unstructured":"Kligman AM. Pathologic dynamics of human hair loss. I. Telogen effuvium. Archives of dermatology. 1961;83:175\u201398.","journal-title":"I. Telogen effuvium. Archives of dermatology."},{"issue":"6","key":"56_CR9","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/j.1365-4362.1982.tb03137.x","volume":"21","author":"G Ioannides","year":"1982","unstructured":"Ioannides G. Alopecia: a pathologist\u2019s view. Int J Dermatol. 1982;21(6):316\u201328.","journal-title":"Int J Dermatol."},{"key":"56_CR10","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/j.1365-2133.1965.tb14614.x","volume":"77","author":"A Rook","year":"1965","unstructured":"Rook A. Some chemical influences on hair growth and pigmentation. Br J Dermatol. 1965;77:115\u201329.","journal-title":"Br J Dermatol."},{"issue":"3","key":"56_CR11","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1365-4362.1995.tb01556.x","volume":"34","author":"PI Pillans","year":"1995","unstructured":"Pillans PI, Woods DJ. Drug-associated alopecia. International journal of dermatology. 1995;34(3):149\u201358.","journal-title":"International journal of dermatology."},{"issue":"3","key":"56_CR12","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1001\/archderm.1957.01550150128021","volume":"75","author":"T Cornbleet","year":"1957","unstructured":"Cornbleet T, Hoit L. Alopecia from coumarin. AMA Arch Derm. 1957;75(3):440\u20131.","journal-title":"AMA Arch Derm."},{"issue":"1","key":"56_CR13","first-page":"63","volume":"42","author":"J Umlas","year":"1988","unstructured":"Umlas J, Harken DE. Warfarin-induced alopecia. Cutis. 1988;42(1):63\u20134.","journal-title":"Cutis."},{"issue":"2","key":"56_CR14","first-page":"71","volume":"4","author":"K Al-Ibrahim","year":"1993","unstructured":"Al-Ibrahim K, Mohammed Z. Warfarin-induced alopecia: case report and review of the literature. Saudi Heart J. 1993;4(2):71.","journal-title":"Saudi Heart J."},{"issue":"8982","key":"56_CR15","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/S0140-6736(95)91781-0","volume":"346","author":"T Nagao","year":"1995","unstructured":"Nagao T, Ibayashi S, Fujii K, Sugimori H, Sadoshima S, Fujishima M. Treatment of warfarin-induced hair loss with ubidecarenone. Lancet. 1995;346(8982):1104\u20135.","journal-title":"Lancet."},{"issue":"1","key":"56_CR16","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/s11239-007-0109-6","volume":"25","author":"WA Leong","year":"2008","unstructured":"Leong WA. Case studies in anticoagulation management. J Thromb Thrombolysis. 2008;25(1):78\u201384.","journal-title":"J Thromb Thrombolysis."},{"issue":"6","key":"56_CR17","first-page":"828","volume":"20","author":"S Nakamizo","year":"2010","unstructured":"Nakamizo S, Egawa G, Arakawa A, Miyachi Y, Kabashima K. Warfarin-induced alopecia after repeated chemotherapy. Eur J Dermatol EJD. 2010;20(6):828\u20139.","journal-title":"Eur J Dermatol EJD."},{"key":"56_CR18","unstructured":"Poquet Jornet J, Pales Argullos A, Portis Espinosa M. Acenocoumarol-induced alopecia: report of three cases. Farm Hosp. 2000;24(5):314\u20138."},{"issue":"4","key":"56_CR19","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1182\/blood.V96.4.1618","volume":"96","author":"C Barnes","year":"2000","unstructured":"Barnes C, Deidun D, Hynes K, Monagle P. Alopecia and dalteparin: a previously unreported association. Blood. 2000;96(4):1618\u20139.","journal-title":"Blood."},{"issue":"9","key":"56_CR20","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.1182\/blood.V97.9.2914","volume":"97","author":"R Apsner","year":"2001","unstructured":"Apsner R, Horl WH, Sunder-Plassmann G. Dalteparin-induced alopecia in hemodialysis patients: reversal by regional citrate anticoagulation. Blood. 2001;97(9):2914\u20135.","journal-title":"Blood."},{"issue":"5","key":"56_CR21","doi-asserted-by":"crossref","first-page":"E15","DOI":"10.1016\/S0272-6386(03)00211-7","volume":"41","author":"E Sarris","year":"2003","unstructured":"Sarris E, Tsele E, Bagiatoudi G, Salpigidis K, Stavrianaki D, Kaklamanis L, et al. Diffuse alopecia in a hemodialysis patient caused by a low-molecular-weight heparin, tinzaparin. Am J Kidney Dis. 2003;41(5):E15.","journal-title":"Am J Kidney Dis."},{"issue":"5","key":"56_CR22","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/j.1365-2710.2006.00769.x","volume":"31","author":"YY Wang","year":"2006","unstructured":"Wang YY, Po HL. Enoxaparin-induced alopecia in patients with cerebral venous thrombosis. J Clin Pharm Thera. 2006;31(5):513\u20137.","journal-title":"J Clin Pharm Thera."},{"issue":"3","key":"56_CR23","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/00000441-195403000-00007","volume":"227","author":"JS Hirschboeck","year":"1954","unstructured":"Hirschboeck JS, Madison FW, Pisciotta AV. Alopecia and other toxic effects of heparin and synthetic heparinoids. Am J Med Sci. 1954;227(3):279\u201382.","journal-title":"Am J Med Sci."},{"key":"56_CR24","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S0031-6997(25)07056-5","volume":"15","author":"P Flesch","year":"1963","unstructured":"Flesch P. Inhibition of keratinizing structures by systemic drugs. Pharmacol Rev. 1963;15:653\u201371.","journal-title":"Pharmacol Rev."},{"issue":"5","key":"56_CR25","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/j.1365-2133.1991.tb00618.x","volume":"124","author":"R Paus","year":"1991","unstructured":"Paus R. Hair growth inhibition by heparin in mice: a model system for studying the modulation of epithelial cell growth by glycosaminoglycans? Br J Dermatol. 1991;124(5):415\u201322.","journal-title":"Br J Dermatol."},{"key":"56_CR26","doi-asserted-by":"crossref","unstructured":"Gelbricht V, Koehler C, Werth S, Haensel U, Schreier T, Luise T, et al. Hair loss is a potential side effect of novel oral anticoagulants-findings from the dresden noac registry (NCT01588119). Blood. 2012;120(21).","DOI":"10.1182\/blood.V120.21.1173.1173"},{"issue":"9","key":"56_CR27","first-page":"1538","volume":"12","author":"E Loizou","year":"2014","unstructured":"Loizou E, Toh C-H, Dutt T. Safe implementation of the new oral anticoagulants (NOACs) requires patient monitoring. J Thromb Haemostasis. 2014;12(9):1538\u20137933.","journal-title":"J Thromb Haemostasis"},{"issue":"2","key":"56_CR28","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","volume":"30","author":"C Naranjo","year":"1981","unstructured":"Naranjo C, Busto U, Sellers E, Sandor P, Ruiz I, Roberts E, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239\u201345.","journal-title":"Clin Pharmacol Ther."}],"container-title":["Drugs - Real World Outcomes"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-015-0056-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40801-015-0056-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-015-0056-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T02:17:29Z","timestamp":1748744249000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40801-015-0056-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,7]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["56"],"URL":"https:\/\/doi.org\/10.1007\/s40801-015-0056-z","relation":{},"ISSN":["2199-1154","2198-9788"],"issn-type":[{"value":"2199-1154","type":"print"},{"value":"2198-9788","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1,7]]}}}